Chardan Capital Has Lowered Expectations for Cognition Therapeutics (NASDAQ:CGTX) Stock Price

Cognition Therapeutics (NASDAQ:CGTX) had its target price dropped by equities research analysts at Chardan Capital from $11.00 to $8.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Several other research analysts have also recently commented on CGTX. B. Riley raised Cognition Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $1.00 to $1.50 in a research note on Thursday, December 19th. Brookline Capital Management raised Cognition Therapeutics to a “strong-buy” rating in a research note on Monday, January 27th. Finally, HC Wainwright boosted their target price on Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, December 19th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Cognition Therapeutics presently has an average rating of “Buy” and an average price target of $7.70.

Cognition Therapeutics Trading Up 6.6 %

Shares of NASDAQ CGTX opened at $0.45 on Friday. Cognition Therapeutics has a twelve month low of $0.34 and a twelve month high of $2.95. The stock has a fifty day simple moving average of $0.58 and a 200-day simple moving average of $0.55. The stock has a market capitalization of $18.90 million, a PE ratio of -0.47 and a beta of 1.03.

Cognition Therapeutics (NASDAQ:CGTX) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). During the same quarter last year, the business earned ($0.27) earnings per share. On average, equities analysts predict that Cognition Therapeutics will post -0.8 earnings per share for the current year.

Institutional Trading of Cognition Therapeutics

A number of institutional investors have recently bought and sold shares of the business. BIOS Capital Management LP purchased a new stake in Cognition Therapeutics during the 4th quarter worth about $4,208,000. Sigma Planning Corp lifted its holdings in Cognition Therapeutics by 211.6% during the 4th quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock worth $431,000 after buying an additional 417,300 shares during the last quarter. Voss Capital LP purchased a new stake in Cognition Therapeutics during the 4th quarter worth about $351,000. Geode Capital Management LLC lifted its holdings in Cognition Therapeutics by 8.9% during the 4th quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock worth $247,000 after buying an additional 28,705 shares during the last quarter. Finally, Virtu Financial LLC lifted its holdings in Cognition Therapeutics by 40.1% during the 4th quarter. Virtu Financial LLC now owns 80,180 shares of the company’s stock worth $56,000 after buying an additional 22,949 shares during the last quarter. 43.35% of the stock is owned by hedge funds and other institutional investors.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.